

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Inflammation				
Allergy	Tumor necrosis factor receptor superfamily member 25 (TNFRSF25; DR3; LARD; TRAMP; WSL-1)	<p>Studies in mice suggest that DR3 agonists could be useful for treating asthma. In mice, a DR3-agonizing mAb caused proliferation of immunosuppressive T_{reg} cells compared with no treatment. In a mouse model of allergic lung inflammation and asthma, the mAb lowered proinflammatory cytokine levels and immune cell infiltration into lungs after allergen challenge compared with control antibodies. Next steps could include characterizing the effect of D3 agonists in models of chronic lung inflammation.</p> <p>Heat Biologics Inc's Medicor DR3-agonizing mAb is in preclinical development for cancer and asthma.</p> <p>SciBX 3(40); doi:10.1038/scibx.2010.1211 Published online Oct. 14, 2010</p>	Patent and licensing status unavailable	<p>Schreiber, T.H. <i>et al.</i> <i>J. Clin. Invest.</i>; published online Sept. 20, 2010; doi:10.1172/JCI42933</p> <p>Contact: Eckhard R. Podack, University of Miami Miller School of Medicine, Miami, Fla. e-mail: epodack@med.miami.edu</p>